Biomea Fusion (Nasdaq:BMEA) - Cotización, noticias y análisis

Resumen de acción BMEA

BMEA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 77.66%

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Biomea Fusion, Inc.

Sagimet Biosciences

NasdaqGM:SGMT

US$152.9m

ProQR Therapeutics

NasdaqCM:PRQR

US$146.2m

Kodiak Sciences

NasdaqGM:KOD

US$144.6m

Werewolf Therapeutics

NasdaqGS:HOWL

US$141.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Biomea Fusion
Historical stock prices
Current Share Price	US$5.64
52 Week High	US$37.09
52 Week Low	US$3.61
Beta	-0.37
1 Month Change	-57.40%
3 Month Change	-68.40%
1 Year Change	-83.86%
3 Year Change	-71.80%
5 Year Change	n/a
Change since IPO	-69.68%

Noticias y actualizaciones recientes

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Jun 10

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Rentabilidad de los accionistas

	BMEA	US Biotechs	Mercado US
7D	36.2%	0.02%	1.2%
1Y	-83.9%	6.7%	20.6%

Rentabilidad vs. Industria: Los resultados de BMEA fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 8.4% el año pasado.

Rentabilidad vs. Mercado: BMEA obtuvo unos resultados inferiores a los del mercado US, que fueron del 21.8% el año pasado.

Volatilidad de los precios

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement	22.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.8%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Precio estable de las acciones: El precio de las acciones de BMEA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BMEA ha aumentado de 17% a 22% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2017	110	Thomas Butler	biomeafusion.com

Biomea Fusion, Inc, empresa biofarmacéutica en fase clínica, se centra en el descubrimiento y desarrollo de fármacos covalentes de moléculas pequeñas para tratar a pacientes con cánceres y enfermedades metabólicas genéticamente definidos. Su principal candidato a producto es BMF-219, un inhibidor covalente de la menina para tratar a pacientes con tumores líquidos y sólidos y diabetes tipo 2. La empresa se constituyó en 2017 y tiene su sede en Redwood City (California).

Resumen de fundamentos de Biomea Fusion, Inc.

¿Cómo se comparan los beneficios e ingresos de Biomea Fusion con su capitalización de mercado?
Estadísticas fundamentales de BMEA
Capitalización bursátil	US$208.84m
Beneficios(TTM)	-US$127.26m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.6x

Ratio precio-beneficio (PE)

¿Está BMEA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BMEA
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$127.27m
Beneficios	-US$127.26m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.54
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BMEA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BMEA

Recompensas

Análisis de riesgos

Competidores de Biomea Fusion, Inc.

NasdaqGM:SGMT

US$152.9m

NasdaqCM:PRQR

US$146.2m

NasdaqGM:KOD

US$144.6m

NasdaqGS:HOWL

US$141.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Recent updates

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022